ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

argenx, AstraZeneca and UCB side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

argenx×AstraZeneca×UCB×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

argenxAstraZenecaUCB
studies on the registry934,197581
open to participants now3029824
phase 3 studies under way1620020
reach primary completion within a year2116814
programswith a study of their own in two years14119+5 named only16

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseargenxAstraZenecaUCB
Phase 1

argenx: 7 of its 14 programs at phase 1

  1. Adimanebart SC - formulation Aphase 1
  2. ARGX-124phase 1
  3. empasiprubart SC AIphase 1
  4. ARGX-109phase 1
  5. ARGX-213phase 1

and 2 more — sign in to see them all

50%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

UCB: 8 of its 16 programs at phase 1

  1. cizutamigphase 1
  2. Bimekizumab regimen 3 scphase 1
  3. Cizutamig will be dosed according to the protocol.phase 1
  4. CND261phase 1
  5. CND319phase 1

and 3 more — sign in to see them all

50%
Phase 2

argenx: 3 of its 14 programs at phase 2

  1. FB102phase 2
  2. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2
  3. ARGX-121phase 2
21%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

UCB: 3 of its 16 programs at phase 2

  1. galvokimigphase 2
  2. glovadalenphase 2
  3. donzakimigphase 2
19%
Phase 3

argenx: 2 of its 14 programs at phase 3

  1. empasiprubartphase 3
  2. adimanebartphase 3
14%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

UCB: 4 of its 16 programs at phase 3

  1. bimekizumabphase 3
  2. zilucoplanphase 3
  3. dapirolizumab pegolphase 3
  4. Fenfluraminephase 3
25%
Approved, new studies

argenx: 2 of its 14 programs at approved, new studies

  1. efgartigimod alfaapproved, new study
  2. hyaluronidase (human recombinant)approved, new study
14%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

UCB: 1 of its 16 programs at approved, new studies

  1. rozanolixizumabapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
argenx9 readouts · 1 phase 3

argenx, Nov ’26: 1 program whose next study reaches primary completion

  1. empasiprubartphase 3 · Nov 0 · NCT06284954

argenx, Dec ’26: 4 programs whose next study reaches primary completion

  1. adimanebartphase 3 · Dec 0 · NCT07673601
  2. Adimanebart SC - formulation Aphase 1 · Dec 0 · NCT07673601
  3. ARGX-124phase 1 · Dec 31 · NCT07377396
  4. FB102phase 2 · Dec 31 · NCT06905873
··

argenx, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. efgartigimod alfaapproved, new study · Mar 0 · NCT04833894
  2. empasiprubart SC AIphase 1 · Mar 0 · NCT07612020
  3. hyaluronidase (human recombinant)approved, new study · Mar 0 · NCT06655155
····

argenx, Aug ’27: 1 program whose next study reaches primary completion

  1. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2 · Aug 24 · NCT06436742
··
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
UCB6 readouts · 2 phase 3·

UCB, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. UCB5285phase 1 · Dec 13 · NCT07286682
  2. bimekizumabphase 3 · Dec 21 · NCT06921850
··

UCB, Mar ’27: 1 program whose next study reaches primary completion

  1. zilucoplanphase 3 · Mar 23 · NCT06961747
·

UCB, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. rozanolixizumabapproved, new study · May 6 · NCT05063162
  2. galvokimigphase 2 · May 17 · NCT07277660

UCB, Jun ’27: 1 program whose next study reaches primary completion

  1. CND261phase 1 · Jun 1 · NCT07052032
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

argenx

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 2

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

UCB

New programs 1

  • UCB0159phase 1 · first study · Sep 24 · Psoriasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 15 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionargenxAstraZenecaUCB
Myasthenia Gravisall three · compare here

argenx in Myasthenia Gravis: 3 programs

  1. empasiprubartphase 3
  2. efgartigimod alfaapproved, new study
  3. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Myasthenia Gravis in search

AstraZeneca in Myasthenia Gravis: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Myasthenia Gravis in search

UCB in Myasthenia Gravis: 3 programs

  1. zilucoplanphase 3
  2. cizutamigphase 1
  3. rozanolixizumabapproved, new study

Their studies: UCB’s studies of Myasthenia Gravis in search

Multiple Myelomaall three · compare here

argenx in Multiple Myeloma: 1 program

  1. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Multiple Myeloma in search

UCB in Multiple Myeloma: 1 program

  1. cizutamigphase 1

Their studies: UCB’s studies of Multiple Myeloma in search

Purpura, Thrombocytopenic, Idiopathicall three · compare here

argenx in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. efgartigimod alfaapproved, new study

Their studies: argenx’s studies of Purpura, Thrombocytopenic, Idiopathic in search

AstraZeneca in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. pirtobrutinibphase 2

Their studies: AstraZeneca’s studies of Purpura, Thrombocytopenic, Idiopathic in search

UCB in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. rozanolixizumabapproved, new study

Their studies: UCB’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Lupus Erythematosus, Systemic2 of 3 · compare here–

UCB in Lupus Erythematosus, Systemic: 2 programs

  1. dapirolizumab pegolphase 3
  2. cizutamigphase 1

Their studies: UCB’s studies of Lupus Erythematosus, Systemic in search

Arthritis, Rheumatoid2 of 3 · compare here–

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

UCB in Arthritis, Rheumatoid: 1 program

  1. CND261phase 1

Their studies: UCB’s studies of Arthritis, Rheumatoid in search

Bronchitis, Chronic2 of 3 · compare here–

AstraZeneca in Bronchitis, Chronic: 2 programs

  1. tozorakimabphase 3
  2. formoterolapproved, new study

Their studies: AstraZeneca’s studies of Bronchitis, Chronic in search

UCB in Bronchitis, Chronic: 1 program

  1. galvokimigphase 2

Their studies: UCB’s studies of Bronchitis, Chronic in search

Dermatitis, Atopic2 of 3 · compare here–

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

UCB in Dermatitis, Atopic: 2 programs

  1. galvokimigphase 2
  2. donzakimigphase 2

Their studies: UCB’s studies of Dermatitis, Atopic in search

Hemoglobinuria, Paroxysmal2 of 3 · compare here–

AstraZeneca in Hemoglobinuria, Paroxysmal: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Hemoglobinuria, Paroxysmal in search

UCB in Hemoglobinuria, Paroxysmal: 1 program

  1. zilucoplanphase 3

Their studies: UCB’s studies of Hemoglobinuria, Paroxysmal in search

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating2 of 3 · compare here

argenx in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 2 programs

  1. empasiprubartphase 3
  2. efgartigimod alfaapproved, new study

Their studies: argenx’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

–

UCB in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 1 program

  1. rozanolixizumabapproved, new study

Their studies: UCB’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Bronchiectasis2 of 3 · compare here–

AstraZeneca in Bronchiectasis: 1 program

  1. AZD0292phase 2

Their studies: AstraZeneca’s studies of Bronchiectasis in search

UCB in Bronchiectasis: 1 program

  1. galvokimigphase 2

Their studies: UCB’s studies of Bronchiectasis in search

COVID-192 of 3 · compare here–

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

UCB in COVID-19: 1 program

  1. zilucoplanphase 3

Their studies: UCB’s studies of COVID-19 in search

Dermatomyositis2 of 3 · compare here

argenx in Dermatomyositis: 1 program

  1. empasiprubartphase 3

Their studies: argenx’s studies of Dermatomyositis in search

AstraZeneca in Dermatomyositis: 1 program

  1. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatomyositis in search

–

Show all 15

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: argenx 1 of 14 · AstraZeneca 68 of 119 · UCB 7 of 16 programs (37 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).